Outcomes analysis of an alternative formulation of PEGylated liposomal doxorubicin in recurrent epithelial ovarian carcinoma during the drug shortage era

BACKGROUND: In response to the critical shortage of Doxil(®), the US Food and Drug Administration (FDA) allowed temporary importation of non-FDA-approved second-generation liposomal doxorubicin, Lipo-Dox(®). Lipo-Dox utilizes a different liposomal particle than Doxil and demonstrates different pharm...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Berger, Jessica L, Smith, Ashlee, Zorn, Kristin K, Sukumvanich, Paniti, Olawaiye, Alexander B, Kelley, Joseph, Krivak, Thomas C
Natura: Artigo
Lingua:Inglês
Pubblicazione: Dove Medical Press 2014
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4133030/
https://ncbi.nlm.nih.gov/pubmed/25143745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S62881
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi